» Articles » PMID: 30581432

Modulation of Immune Tolerance Via Siglec-Sialic Acid Interactions

Overview
Journal Front Immunol
Date 2018 Dec 25
PMID 30581432
Citations 116
Authors
Affiliations
Soon will be listed here.
Abstract

One of the key features of the immune system is its extraordinary capacity to discriminate between self and non-self and to respond accordingly. Several molecular interactions allow the induction of acquired immune responses when a foreign antigen is recognized, while others regulate the resolution of inflammation, or the induction of tolerance to self-antigens. Post-translational signatures, such as glycans that are part of proteins (glycoproteins) and lipids (glycolipids) of host cells or pathogens, are increasingly appreciated as key molecules in regulating immunity vs. tolerance. Glycans are sensed by glycan binding receptors expressed on immune cells, such as C-type lectin receptors (CLRs) and Sialic acid binding immunoglobulin type lectins (Siglecs), that respond to specific glycan signatures by triggering tolerogenic or immunogenic signaling pathways. Glycan signatures present on healthy tissue, inflamed and malignant tissue or pathogens provide signals for "self" or " recognition. In this review we will focus on sialic acids that serve as "self" molecular pattern ligands for Siglecs. We will emphasize on the function of Siglec-expressing mononuclear phagocytes as sensors for sialic acids in tissue homeostasis and describe how the sialic acid-Siglec axis is exploited by tumors and pathogens for the induction of immune tolerance. Furthermore, we highlight how the sialic acid-Siglec axis can be utilized for clinical applications to induce or inhibit immune tolerance.

Citing Articles

Variability of Sialic Acids in Beef Breeds and Nutritional Implications in Red Meat.

Conto M, Miarelli M, Di Giovanni S, Failla S Molecules. 2025; 30(3).

PMID: 39942813 PMC: 11821032. DOI: 10.3390/molecules30030710.


Glycoscience in Advancing PD-1/PD-L1-Axis-Targeted Tumor Immunotherapy.

Sun Q, Hong S Int J Mol Sci. 2025; 26(3).

PMID: 39941004 PMC: 11818636. DOI: 10.3390/ijms26031238.


Interactions of human milk oligosaccharides with the immune system.

Slater A, Hickey R, Davey G Front Immunol. 2025; 15:1523829.

PMID: 39877362 PMC: 11772441. DOI: 10.3389/fimmu.2024.1523829.


Targeting protein modification: a new direction for immunotherapy of pancreatic cancer.

Ge X, Zhang K, Zhu J, Chen Y, Wang Z, Wang P Int J Biol Sci. 2025; 21(1):63-74.

PMID: 39744438 PMC: 11667816. DOI: 10.7150/ijbs.101861.


Interleukin in Immune-Mediated Diseases: An Updated Review.

Zaroon , Aslam S, Hafsa , Mustafa U, Fatima S, Bashir H Mol Biotechnol. 2024; .

PMID: 39715931 DOI: 10.1007/s12033-024-01347-8.


References
1.
Bull C, Collado-Camps E, Kers-Rebel E, Heise T, Sondergaard J, den Brok M . Metabolic sialic acid blockade lowers the activation threshold of moDCs for TLR stimulation. Immunol Cell Biol. 2016; 95(4):408-415. DOI: 10.1038/icb.2016.105. View

2.
Kantarjian H, DeAngelo D, Stelljes M, Martinelli G, Liedtke M, Stock W . Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. N Engl J Med. 2016; 375(8):740-53. PMC: 5594743. DOI: 10.1056/NEJMoa1509277. View

3.
Angata T, Varki A . Chemical diversity in the sialic acids and related alpha-keto acids: an evolutionary perspective. Chem Rev. 2002; 102(2):439-69. DOI: 10.1021/cr000407m. View

4.
Kosten I, van de Ven R, Thon M, Gibbs S, de Gruijl T . Comparative phenotypic and functional analysis of migratory dendritic cell subsets from human oral mucosa and skin. PLoS One. 2017; 12(7):e0180333. PMC: 5509153. DOI: 10.1371/journal.pone.0180333. View

5.
Spence S, Greene M, Fay F, Hams E, Saunders S, Hamid U . Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation. Sci Transl Med. 2015; 7(303):303ra140. DOI: 10.1126/scitranslmed.aab3459. View